Therefore, in this study, we characterized the clinical and molecular features of HER2 amplification in CRC and investigated the differential incidence of RAS/RAF and PIK3CA alterations in patients with HER2-amplified colon and rectal cancer. The gene discussed is PIK3CA; the disease is colorectal carcinoma.